Valuation: argenx SE

Market Cap 54.57B 48.97B 45.22B 41.01B 76.64B 5,183B 77.58B 542B 215B 2,717B 205B 200B 8,615B P/E 2026 *
30x
P/E 2027 * 25.9x
Enterprise Value 50.74B 45.54B 42.05B 38.13B 71.27B 4,820B 72.15B 504B 200B 2,526B 190B 186B 8,011B EV / Sales 2026 *
7.96x
EV / Sales 2027 * 6.26x
Free-Float
99.99%
Yield 2026 *
0.05%
Yield 2027 * 0.09%
1 day+1.51%
1 week+1.47%
Current month-7.97%
1 month-9.23%
3 months-0.71%
6 months+12.60%
Current year+4.94%
1 week 853.28
Extreme 853.28
897.27
1 month 787.73
Extreme 787.73
977.01
Current year 661.85
Extreme 661.85
1,072.75
1 year 661.85
Extreme 661.85
1,072.75
3 years 327.72
Extreme 327.725
1,072.75
5 years 249.5
Extreme 249.5
1,072.75
10 years 17.33
Extreme 17.33
1,072.75
Manager TitleAgeSince
Chief Executive Officer 47 06/05/2026
Director of Finance/CFO 56 01/06/2021
Chief Tech/Sci/R&D Officer - 01/01/2015
Director TitleAgeSince
Chairman 54 06/05/2026
Director/Board Member 76 13/05/2015
Director/Board Member 65 28/04/2016
Change 5-day change 1-year change 3-year change Capi.($)
+1.51%+1.47% - - 54.57B
-3.10%-3.43%+36.29%+67.69% 65.28B
+0.33%+7.26%+11.51%+77.95% 54.57B
+0.16%+3.69%+8.39%+101.27% 53.59B
-0.75%+1.38%+24.89%+50.91% 45.03B
-1.30%-4.80%+16.05%+114.76% 42.17B
+1.26%-5.26%+221.12%+900.64% 39.42B
-0.74%-4.84%+14.53%+44.45% 32.71B
-2.70%-7.34%+23.17%+0.36% 24.01B
+1.11%+17.90%+56.87%+47.78% 26.5B
Average -0.43%+1.98%+45.87%+156.20% 42.59B
Weighted average by Cap. -0.45%+1.72%+43.05%+155.14%

Financials

2026 *2027 *
Net sales 6.37B 5.72B 5.28B 4.79B 8.95B 605B 9.06B 63.31B 25.14B 317B 23.92B 23.41B 1,006B 7.77B 6.98B 6.44B 5.84B 10.92B 738B 11.05B 77.25B 30.68B 387B 29.18B 28.56B 1,227B
Net income 1.83B 1.64B 1.51B 1.37B 2.56B 173B 2.6B 18.14B 7.2B 90.9B 6.85B 6.71B 288B 2.11B 1.9B 1.75B 1.59B 2.97B 201B 3B 20.99B 8.34B 105B 7.93B 7.76B 334B
Net Debt -3.82B -3.43B -3.17B -2.87B -5.37B -363B -5.43B -37.97B -15.08B -190B -14.35B -14.04B -603B -5.91B -5.3B -4.9B -4.44B -8.3B -561B -8.4B -58.7B -23.31B -294B -22.18B -21.7B -933B
Projected Income Statement - Annual - argenx SE
Logo argenx SE
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE developed and is commercializing the first approved neonatal Fc receptor (FcRn) blocker and is evaluating its broad potential in multiple serious autoimmune diseases while advancing several earlier stage experimental medicines within its therapeutic franchises.
Employees
1,863
Date Price Change Volume
27/10/26 $882.48 +1.51% 290,150
26/10/26 $869.33 -0.50% 269,569
23/10/26 $873.71 -0.23% 298,965
22/10/26 $875.76 -1.61% 1,020,771
21/10/26 $890.05 +2.34% 656,687
Trader
Investor
Global
Quality
ESG MSCI
-
MarketScreener Ratings - argenx SE
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
15
Last Close Price
872.51USD
Average target price
1,121.87USD
Spread / Average Target
+28.58%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - argenx SE